Recipharm: Q2 rev up on M&As, higher demand and anti-radiation med

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Revenue

ex-Alcon facility in France was acquired by Recipharm in 2015
ex-Alcon facility in France was acquired by Recipharm in 2015
Acquisitions, higher demand for sterile liquid processing and a surge in Thyrosafe orders helped Recipharm offset pricing pressure in Portugal and lower UK sales in Q2.

The Sweden-based contractor posted revenue of SEK1.23bn ($143m) for the three months to the end of June. Operating profit in the period was SEK150m, up 61% and margins improved from 17.9% to 19.4%.

Recipharm attributed the revenue growth to contributions from acquisitions over the past 12 months - OT Chemistry AB, Mitim Srl, Nitin Lifesciences Ltd, Kemwell AB and Cirrus Pharmacuticals Inc - which contributed SEK 230.7m in the quarter.

It also said higher than expected demand for blow-fill-seal (BFS) services at a facility in Kaysersberg, France it acquired from Novartis’ Alcon unit last year​ had increased revenue for the quarter.

A spokesman told us: “We have seen good volume development from the [Alcon] contract at a higher than anticipated rate. We also see good demand going forward for the technology, which is one of the factors behind our recent expansion announcement​.”

Earlier this month the firm said it would invest €18m ($20m) to up BFS capacity at the facility, citing demand from customers in “markets including the US, Turkey, Australia and Canada​” as the motivation.

Quarterly revenue was also boosted by sales of Recipharm’s anti-radiation drug Thyrosafe.

Other products fared less well. Recipharm reported that lower reference prices in Portugal and lower sales in the UK of high-margin own products had a negative impact.

The spokesman told us the UK products had been impacted by increased competition, adding that “the weaker pound did not help matters in this regard when the sales translate in SEK​.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars